Reply
- PMID: 33160643
- DOI: 10.1016/j.jaci.2020.09.025
Reply
Comment on
-
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Clinical Trial.
-
Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis.J Allergy Clin Immunol. 2021 Jan;147(1):413. doi: 10.1016/j.jaci.2020.09.024. Epub 2020 Nov 5. J Allergy Clin Immunol. 2021. PMID: 33160644 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources